摘要
目的:评价国产与进口吉西他滨治疗晚期非小细胞肺癌(NSCLC)的疗效和安全性差异。方法:系统检索Medline、EM-base、Cochrane图书馆、CBM、CNKI、VIP数据库,纳入国产与进口吉西他滨治疗晚期NSCLC的临床研究,并进行质量评价和Meta分析。结果:共纳入8个符合标准的研究,其中1个为临床对照试验,7个为随机对照试验。Meta分析结果显示,2组完全缓解率和总有效率差异无统计学意义[RR及95%CI分别为0.77(0.34,1.76)、1.00(0.81,1.23)],纳入分析的安全性指标差异也无统计学意义。结论:国产与进口吉西他滨联合顺铂治疗晚期NSCLC的疗效和安全性相似。
To review the effect and safety of domestic compared with imported gemcitabine for the treatment of non-small-cell lung cancer （NSCLC）. METHODS： Databases of Medline, EMBase, the Cochrane library, CBM, CNKI and VIP were searched, clinical studies of domestic compared with imported gemcitabine for the treatment of NSCLC were included for quality analysis and meta-analysis. RESULTS： 8 studies were gathered, 1 was clinical controlled trail and 7 were randomized con- trolled trails. Meta-analysis indicated that the difference of complete remission rate and total effective rate were note significant： the RR and 95%CI were 0.77（0.34, 1.76）, 1.00（0.81, 1.23）, respectively. CONCLUSION： For the treatment of NSCLC, the clinical effect and safety of domestic and imported gemcitabine were almost the same.
出处
《中国药房》
CAS
CSCD
北大核心
2011年第12期1119-1121,共3页
China Pharmacy
